Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFEND 2A: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes in Adolescents
2010-022549-59Phase 3Terminated
- Sponsor
- Tolerx, Inc.
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Otelixizumab with Placebo (2 arms). Primary endpoint: Change from baseline in 2-hour mixed meal-stimulated C-peptide AUC at Month 12. Started Oct 2010; status: terminated.
02
Drugs
otelixizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2010-022549-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022549-59.